Compare BridgeBio Pharma Inc (BBIO) vs Brookfield Infrastructure Partners LP (BIP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs Brookfield Infrastructure Partners LP — how do they compare? BridgeBio Pharma Inc trades at $84.09 (market cap $16.46B), while Brookfield Infrastructure Partners LP trades at $38.19 (market cap $17.38B). The key difference: BridgeBio Pharma Inc and Brookfield Infrastructure Partners LP are close in size by market cap, and Brookfield Infrastructure Partners LP pays a 4.77% dividend while BridgeBio Pharma Inc pays none. Which is the better fit depends on your goals.
| BBIO | BIP | |
|---|---|---|
Market Cap | $16.46B | $17.38B |
Sector | Health | Industrials |
52-Week High | $90.17 | $40.08 |
52-Week Low | $44.81 | $29.81 |
Enterprise Value | $18.02B | $79.06B |
Dividend Yield | — | 4.77% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $83.08, down 3.27% today, near its 52-week high. The stock shows bullish technical momentum with strong moving averages, while fundamentals reveal rapid revenue growth to $502M in 2025 but persistent losses with a -144.4% net margin. Recent news highlights regulatory approvals for acoramidis and a $1B preferred equity raise to fund launches, driving positive sentiment despite earnings misses.
Outlook remains speculative with high execution risk; analyst consensus is strongly bullish (92% buy) targeting $104.57, but profitability challenges and heavy cash burn require successful pipeline commercialization to justify valuation. Key near-term catalysts include FDA decisions on BBP-418 and encaleret in 2026.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About Brookfield Infrastructure Partners LP
Brookfield Infrastructure owns and operates high-quality global assets across utilities, transport, midstream, and data sectors. It focuses on generating stable, long-term cash flows from essential infrastructure.
Read more on BIP →
